HARMONY BIOSCIENCES ($HRMY) posted quarterly earnings results for Q2 2026 on Tuesday, August 4th. The company reported earnings of $1.28 per share, beating estimates of $1.02 by $0.26. The company also reported revenue of $261,279,999, beating estimates of $253,374,324 by $7,905,675.
You can see Quiver Quantitative's $HRMY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
HARMONY BIOSCIENCES Hedge Fund Activity
We have seen 155 institutional investors add shares of HARMONY BIOSCIENCES stock to their portfolio, and 129 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 1,124,000 shares (+224.8%) to their portfolio in Q1 2026, for an estimated $31,483,240
- SG AMERICAS SECURITIES, LLC added 1,056,507 shares (+109.9%) to their portfolio in Q1 2026, for an estimated $29,592,761
- MILLENNIUM MANAGEMENT LLC added 722,663 shares (+311.9%) to their portfolio in Q1 2026, for an estimated $20,241,790
- GOLDMAN SACHS GROUP INC added 669,845 shares (+117.6%) to their portfolio in Q1 2026, for an estimated $18,762,358
- BOSTON PARTNERS removed 666,000 shares (-93.9%) from their portfolio in Q1 2026, for an estimated $18,654,660
- TWO SIGMA INVESTMENTS, LP added 526,490 shares (+254.4%) to their portfolio in Q1 2026, for an estimated $14,746,984
- 683 CAPITAL MANAGEMENT, LLC removed 415,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $11,624,150
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
HARMONY BIOSCIENCES Government Contracts
We have seen $708,171 of award payments to $HRMY over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- BULK - WAKIX 17.8MG TAB: $635,244
- WAKIX 17.8 MG: $10,418
- WAKIX 17.8 MG: $10,418
- WAKIX 17.8 MG: $10,418
- WAKIX 17.8 MG: $10,418
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
HARMONY BIOSCIENCES Analyst Ratings
Wall Street analysts have issued reports on $HRMY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Underperform" rating on 02/25/2026
- Needham issued a "Buy" rating on 02/25/2026
To track analyst ratings and price targets for HARMONY BIOSCIENCES, check out Quiver Quantitative's $HRMY forecast page.
HARMONY BIOSCIENCES Price Targets
Multiple analysts have issued price targets for $HRMY recently. We have seen 7 analysts offer price targets for $HRMY in the last 6 months, with a median target of $36.0.
Here are some recent targets:
- David Hoang from Deutsche Bank set a target price of $36.0 on 06/30/2026
- Danielle Brill from Truist Securities set a target price of $29.0 on 05/08/2026
- Jason Gerberry from B of A Securities set a target price of $28.0 on 02/25/2026
- Ami Fadia from Needham set a target price of $44.0 on 02/25/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $55.0 on 02/25/2026
- So Youn Shim from UBS set a target price of $36.0 on 02/25/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
